Epigenetic Markers of Cancer Development and Progression

Dear Colleagues,

Epigenetic mechanisms are essential for normal human development and the maintenance of tissue-specific gene expression in mammals by controlling DNA methylation profiles, non-coding RNA expression, and histone modifications. In the context of cancer, gene expression reprogramming and malignant transformation can occur when epigenetic processes and genetic alterations are dysregulated. "Nonmutational epigenetic reprogramming" is recognized as one of the hallmarks of cancer, being fundamental for cancer cell transformation.

High-throughput techniques have made it easier to understand the significance of epigenetic alterations from the early stages of cancer to potential anti-tumor therapies. A deeper understanding of the patterns of epigenetic modifications and their corresponding changes in cancer will improve our understanding of malignant tumor biology and also assist in developing better treatment strategies. A combination of therapies, including an epigenetic approach, may be effective against cancer in the future. Therefore, this Special Issue is extremely relevant to all research areas aimed at a comprehensive understanding of these epigenetic alterations in cancer.

We welcome original research articles and reviews in this Special Issue. Research areas may include, but are not limited to: cancer development and/or progression, epigenetic alterations, the cancer epigenome, epigenetic cancer treatment, cancer progression, DNA methylation, non-coding RNA, and histone modifications.

We would be delighted if you consented to contribute your paper to this Special Issue.

Dr. Tatiana de Almeida Simão
Guest Editor

Dr. Pedro Nicolau Neto
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer development
• cancer progression
• epigenetic alterations
• the cancer epigenome
• epigenetic cancer treatment
• DNA methylation
• non-coding RNA
• histone modifications